Home Physical Sciences The crystal structure of the salt: 4-((1,3-dioxoisoindolin-2-yl)carbamoyl)pyridine-1-ium 2-carboxybenzoate, C14H10N3O3·C8H5O4
Article Open Access

The crystal structure of the salt: 4-((1,3-dioxoisoindolin-2-yl)carbamoyl)pyridine-1-ium 2-carboxybenzoate, C14H10N3O3·C8H5O4

  • Mark G. Smith ORCID logo EMAIL logo
Published/Copyright: November 1, 2023

Abstract

C14H10N3O3·C8H5O4, triclinic, P 1 (no. 2), a = 8.1312(3) Å, b = 10.5732(4) Å, c = 12.0961(4) Å, α =  110.933 ( 2 ) , β =  101.603 ( 2 ) , γ =  91.295 ( 2 ) , V = 946.37(6) Å3, Z = 2, R g t (F) = 0.0493, w R r e f (F2) = 0.1369, T = 173 K.

CCDC no.: 2295386

Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless needle
Size: 0.47 × 0.12 × 0.11 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.12 mm−1
Diffractometer, scan mode: Bruker D8 Venture Photon, ω
θmax, completeness: 28.0°, >99 %
N(hkl)measuredN(hkl)uniqueRint: 14,217, 4561, 0.045
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), 2937
N(param)refined: 299
Programs: Bruker [1], SHELX [2, 3], WinGX/ORTEP-3 [4, 5], PLATON [6]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
C1 0.5449 (2) 0.16425 (18) 0.46116 (15) 0.0262 (4)
C2 0.5811 (2) 0.24257 (18) 0.59650 (15) 0.0242 (4)
C3 0.5145 (2) 0.36283 (19) 0.65133 (16) 0.0287 (4)
H3 0.437264 0.399733 0.603863 0.034*
C4 0.5618 (3) 0.4278 (2) 0.77525 (16) 0.0322 (5)
H4 0.514936 0.509225 0.813737 0.039*
C5 0.7394 (3) 0.26249 (19) 0.79175 (16) 0.0306 (5)
H5 0.818914 0.229485 0.841257 0.037*
C6 0.6934 (2) 0.19145 (18) 0.66885 (15) 0.0278 (4)
H6 0.738003 0.10787 0.633413 0.033*
C7 0.5057 (3) 0.2320 (2) 0.21158 (17) 0.0360 (5)
C8 0.4229 (3) 0.1658 (2) 0.08092 (17) 0.0389 (5)
C9 0.4670 (3) 0.1833 (2) −0.01673 (19) 0.0482 (6)
H9 0.558923 0.2469 −0.005792 0.058*
C10 0.3744 (4) 0.1060 (3) −0.1309 (2) 0.0541 (7)
H10 0.402815 0.115695 −0.20008 0.065*
C11 0.2406 (4) 0.0145 (3) −0.1459 (2) 0.0607 (8)
H11 0.177295 −0.0371 −0.225503 0.073*
C12 0.1953 (3) −0.0042 (3) −0.0451 (2) 0.0536 (7)
H12 0.104157 −0.067956 −0.054859 0.064*
C13 0.2909 (3) 0.0752 (2) 0.06797 (17) 0.0410 (6)
C14 0.2794 (3) 0.0800 (2) 0.19166 (19) 0.0374 (5)
N1 0.4383 (2) 0.21912 (18) 0.39431 (13) 0.0362 (4)
N2 0.6728 (2) 0.37790 (16) 0.84223 (14) 0.0301 (4)
N3 0.4174 (2) 0.16765 (17) 0.26974 (13) 0.0348 (4)
O1 0.61114 (18) 0.06184 (13) 0.41769 (11) 0.0355 (4)
O2 0.6216 (2) 0.31991 (16) 0.26162 (14) 0.0491 (4)
O3 0.1775 (2) 0.02278 (16) 0.22208 (15) 0.0500 (4)
H2 0.706 (3) 0.425 (2) 0.926 (2) 0.06*
C15 0.1524 (3) 0.4397 (2) 0.34621 (17) 0.0317 (5)
C16 0.0454 (2) 0.55637 (18) 0.35745 (15) 0.0256 (4)
C17 −0.0721 (2) 0.57976 (18) 0.26479 (15) 0.0259 (4)
C18 −0.1433 (3) 0.70270 (19) 0.29432 (17) 0.0331 (5)
H18A −0.2186 0.720511 0.23181 0.04*
C19 −0.1093 (3) 0.7999 (2) 0.41054 (18) 0.0376 (5)
H19A −0.1594 0.883056 0.427275 0.045*
C20 −0.0016 (3) 0.7741 (2) 0.50174 (17) 0.0369 (5)
H20A 0.0197 0.838038 0.582865 0.044*
C21 0.0750 (3) 0.6555 (2) 0.47516 (16) 0.0313 (5)
H21A 0.15074 0.640106 0.53886 0.038*
C22 −0.1345 (3) 0.4846 (2) 0.13344 (16) 0.0321 (5)
O4 0.25504 (19) 0.44073 (15) 0.43538 (12) 0.0408 (4)
O5 0.1388 (2) 0.34188 (16) 0.24257 (14) 0.0564 (5)
O6 −0.0670 (2) 0.37799 (15) 0.08790 (13) 0.0526 (5)
O7 −0.2573 (2) 0.51703 (15) 0.07231 (12) 0.0453 (4)
H5A 0.056 (4) 0.354 (3) 0.174 (2) 0.068*
H1 0.383 (3) 0.295 (2) 0.421 (2) 0.049 (7)*

1 Source of materials

All reagents were commercially available and used without further purification. An amount of 0.1123 g of isonicotinic acid hydrazide (0.819 mmol), 0.1364 g of phthalic acid (0.821 mmol), 0.1619 g of 2,2-dihydroxybenzophenone (0.818 mmol) and 3.0 mL of methanol were added into a screw-top dram vial (with rubber septum) and stirred at 300 rpm at 60 °C for 10 min. The vial was closed, and the solution was allowed to reflux at 60 °C for 24 h. The solution was then left slightly open to allow slow evaporation at room temperature. Colourless needles were observed after 3 days.

2 Experimental details

C-bound hydrogen atoms were located in the difference map then positioned geometrically and were allowed to ride on their respective parent atoms with thermal displacement parameters 1.2 times of the parent C atom. The coordinates and isotropic displacement parameters of all N-bound and O-bound H atoms were allowed to refine freely. Diagrams and publication material were generated using ORTEP-3 [4], WinGX [5] and PLATON [6].

3 Comment

For over 50 years, isoniazid has been used as a first-line pharmaceutical drug for the treatment of Mycobacterium tuberculosis. However, the mycobacterium has developed resistance to isoniazid due to certain genetic mutations (Shehzad et al. [7]). It is therefore beneficial to modify the NH2 functional group of isoniazid, as this covalent modification has often shown to be effective against multi-drug resistant tuberculosis strains (Setshedi et al. [8]). In this study, isoniazid was covalently modified with phthalic acid, and a salt was formed from an interaction with a second phthalic acid molecule, resulting in the product presented here.

As shown in the figure, the asymmetric unit contains a salt formed via one molecule of 4-((1,3-dioxoisoindolin-2-yl)carbamoyl)pyridine-1-ium and one molecule of 2-carboxybenzoate. The two molecules are held together by a hydrogen bond between H2 on the pyridinium ring and O7 of the carboxylate moiety on the phthalic acid molecule. Furthermore, a hydrogen bond exists between the H1 donor on the carbohydrazide moiety of the modified isoniazid and the O4 acceptor atom of the carboxylic acid moiety of phthalic acid. The carboxylic acid and carboxylate moieties on phthalic acid form an expected intramolecular S(6) hydrogen bond [9], between the H5a donor and the O6 acceptor. All bond lengths and angles are as expected [1011].


Corresponding author: Mark G. Smith, Chemistry Department, University of South Africa, Unisa Science Campus, 28 Pioneer Avenue, Florida, Roodepoort, Gauteng, South Africa, E-mail:

  1. Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by the University of South Africa.

  3. Conflict of interest statement: The author declares no conflict of interest regarding this article.

References

1. Bruker. APEX2 (Version 2012.10-0), SAINT (Version 27B), SADABS (Version 2012/1); Bruker AXS Inc: Madison, Wisconsin, USA, 2012.Search in Google Scholar

2. Sheldrick, G. M. SHELXTL – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar PubMed PubMed Central

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Farrugia, L. J. WINGX and ORTEP for Windows: an update. J. Appl. Crystallogr. 2012, 45, 849–854; https://doi.org/10.1107/s0021889812029111.Search in Google Scholar

5. Farrugia, L. J. WINGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837–838; https://doi.org/10.1107/s0021889899006020.Search in Google Scholar

6. Spek, A. L. Structure validation in chemical crystallography. Acta Crystallogr. 2009, D65, 148–155; https://doi.org/10.1107/s090744490804362x.Search in Google Scholar

7. Shehzad, A., Rehman, G., Ul-Islam, M., Khattak, W. A., Lee, Y. S. Challenges in the development of drugs for the treatment of tuberculosis. Braz. J. Infect. Dis. 2013, 17, 74–81; https://doi.org/10.1016/j.bjid.2012.10.009.Search in Google Scholar PubMed PubMed Central

8. Setshedi, I. B., Lemmerer, A., Smith, M. G. Co-crystallization of N′-benzylidenepyridine-4-carbohydrazide and benzoic acid via autoxidation of benzaldehyde. Acta Crystallogr. 2023, E79, 682–685; https://doi.org/10.1107/s2056989023005698.Search in Google Scholar

9. Bernstein, J., Davis, R. E., Shimoni, L., Chang, N. L. Patterns in hydrogen bonding: functionality and graph set analysis in crystals. Angew. Chem., Int. Ed. 1995, 34, 1555–1573; https://doi.org/10.1002/anie.199515551.Search in Google Scholar

10. Lemmerer, A., Bernstein, J., Kahlenberg, V. One-pot covalent and supramolecular synthesis of pharmaceutical co-crystals using the API isoniazid: a potential supramolecular reagent. CrystEngComm 2010, 12, 2856–2864; https://doi.org/10.1039/c000473a.Search in Google Scholar

11. Turdybekov, K. M., Nurkenov, O. A., Fazylov, S. D., Makhmutova, A. S., Turdybekov, D. M., Seilkhanov, T. M., Arinova, A. E. Synthesis, crystal structure, and conformation of N-isonicotinoylphthalimide. J. Struct. Chem. 2021, 62, 1279–1284; https://doi.org/10.1134/s0022476621080151.Search in Google Scholar

Received: 2023-09-20
Accepted: 2023-10-20
Published Online: 2023-11-01
Published in Print: 2023-12-15

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of bis(dimethylammonium) poly[(μ4-1,1′-(1,4-phenylenebis(methylene))bis(1H-pyrazole-3,5-dicarboxylato))-κ6O1, N2:O2:O3:O1′,N2′]nickel (II)], C22H26N6NiO8
  4. Hydrothermal synthesis and crystal structure of catena-poly[diaqua-bis(μ2-4-((pyridin-4-ylmethyl)amino)benzoato-κ2N:O)cobalt(II)] 4,4′-bipyridine – water (1/2/2)
  5. Crystal structure of (2S,3S,4S,5S, Z)-2,3,5,6-tetrakis(benzyloxy)-4-hydroxyhexanal oxime, C34H37NO6
  6. The crystal structure of hexakis(3-thiophenecarboxylato-κ2O,O″)-bis(1,10-phenanthroline-κ2N,N′) trimanganese(II), C54H34N4O12S6Mn3
  7. Crystal structure of catena-poly[(μ2-1,4-di(pyridin-4-yl)benzene-κ2N:N′)-(4-bromobenzoate-κ2O:O′)-(μ-2-bromobenzoate-κ2O,O′)nickel(II)] – water (2/1), C30H21Br2N2NiO4.5
  8. The crystal structure of poly[(μ3-1,3-phenylenedioxydiacetate-κ5O,O,O′,O″,O‴)-bis(4′-(4-(1H-imidazol-1-yl)phenyl)-4,2′:6′,4″-terpyridine-kN) cadmium(II)], C58H42CdN10O6
  9. The crystal structure of 5-chloro-6′-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3′-bipyridin]-1′-ium 4-methylbenzenesulfonate
  10. Crystal structure of poly[(μ-benzoato)-(μ-cis-4–hydroxy-D-proline)lithium], C12H14LiNO5
  11. The crystal structure of catena-poly[aqua-(4-iodopyridine-2,6-dicarboxylato-κ3N,O,O)-copper(II)] monohydrate, C7H6NO6ICu
  12. The crystal structure of catena-[diaqua-(4-acetylphenoxyacetato-κ2O,O)-bis(4-acetylphenoxyacetato-κ3O,O:O)-dihydrate-lanthanum(III)]–4,4′-bipyridine (2/1), C35H35NO14La
  13. The crystal structure of catena-poly[(4-iodopyridine-2,6-dicarboxylato-κ4 O,N,O′,O′′)(4-imidazol-1-yl-pyridine-κN)copper(II)], C15H9N4O4ICu
  14. Crystal structure of polybis(μ 4-3,5-dicarboxylatopyrazol-1-yl)-bis(N,N-dimethylformamide)tri-copper(II)–acetonitrile (1/2), C20H22Cu3N8O10
  15. Crystal structure of poly[(μ2-5-hydroxy-isophthalato-κ4O,O′:O″,O‴)-(μ2-1,5-bis(imidazol-2-methyl)pentane-κ2N:N′)cadmium(II)], C21H24CdN4O5
  16. The crystal structure of poly[bis(μ2-1,4-bi(1-imidazolyl)benzene-κ2N:N′)bis(μ2-4,4′-methylenebis(3-hydroxy-2-naphthoate)-κ2O:O′)cobalt(II)], C35H24CoN4O6
  17. The crystal structure of a cobalt-vanadium-oxido hydrate
  18. The crystal structure of catena-poly[(μ 2-2H-1,2,3-triazole-4,5-dicarboxylato-κ 2 O, O′)-(μ 2-1,3-bis((1H-imidazol-1-yl)methyl)benzene-κ 2 N,N′) zinc(II)], C18H15N7O4Zn
  19. Crystal structure of poly[diaqua-(bis(m2-1,4-bis(imidazol-1-ylmethyl)benzene)-κ2N,N′-manganese] dichloride, C28H32MnN8O2Cl2
  20. The crystal structure of 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino [3,2-a]isoquinolin-7-ium (E)-3-(4-nitrophenyl)acrylate pentahydrate, C29H34N2O13
  21. Crystal structure of poly[(μ6-ammoniotris(methylene))tris(hydrogen phosphonato)cadmium(II)], C3H10CdNO9P3
  22. Crystal structure of Zn2[(1,1′-(hexane-1,6-diyl)bis(3-(pyridin-3-yl)urea))·(H2O)2·(DMF)2·(SO4)2], C24H50N8O18S2Zn2
  23. The crystal structure of 2-anilino-1,4-naphthoquinone, C10H11NO2
  24. Crystal structure of (E)-2-(2-(4-(diethylamino)styryl)-1-ethyl-1,4-dihydroquinolin-4-yl) malononitrile, C26H26N4
  25. Crystal structure of ethyl 2-((2,6-dichloro-4-(cyanomethyl)phenyl) amino)benzoate, C17H14Cl2N2O2
  26. Synthesis and crystal structure of 2-(3-oxo-3-phenylpropyl)isoindoline-1,3-dione, C17H13NO3
  27. The crystal structure of bis(acetonitrile-κ1N)tetrakis(μ2-2,6-difluorobenzoato-κ2O:O′)rhodium(II) (Rh–Rh), C32H18F8O8N2Rh2
  28. The crystal structure of a new polymorph of 6-hydroxy-2-naphthoic acid, C11H8O3
  29. The crystal structure of [(8-carboxymethoxy-quinoline-2-carboxylate-κ4N,O,O,O)-2,2′-bipyridine-κ2N-copper(II)] tetrahydrate, C22H23N3O9Cu
  30. The crystal structure of ethyl 4-hydroxy-2-(4-methoxyphenyl)-5-oxo-1-(2-oxo-2H-chromen-6-yl)-2,5-dihydro-1H-pyrrole-3-carboxylate, C23H19NO7
  31. Crystal structure of 7-hydroxy-3,4-dihydronaphthalen-1(2H)-one, C10H10O2
  32. Crystal structure of bis(tetrapropylammonium) dodecacarbonyltetratelluridotetraferrate(2-), (Pr4N)2[Fe4Te4(CO)12]
  33. The crystal structure of poly[bis(μ2−3−aminopyridine−4−carboxylatoκ2N:O)Zinc(II)], [Zn(C6H5N2O2)2] n
  34. The crystal structure of methyl 5-nitro-2-(tosyloxy)benzoate, C15H13NO7S
  35. The crystal structure of 18-crown-6 ― tetraaqua-dichlorido-di-μ2-chloridodicopper(II) (2/1), C12H32O10Cu2Cl4
  36. Crystal structure of 6,6a,7,8,9,10-hexahydro-5H-pyrazino [2,3-e]pyrido[1,2-a]pyrazine, C10H14N4
  37. Crystal structure of catena-poly-{diaqua-bis[μ-(((4-chlorophenyl)sulfonyl)glycinato-κO)](μ2-4, 4′-bipyridine-κ2N:N′)cobalt(II)} dihydrate, C26H30Cl2CoN4O12S2
  38. Crystal structure of bis{N′-[1,3-diphenylprop-2-en-1-ylidene]-N-phenylcarbamohydrazonothioato}zinc(II), C44H36N6S2Zn
  39. Crystal structure of tetraaqua-bis(((4-chlorophenyl)sulfonyl)glycinato-κO)cobalt(II) dihydrate, C16H26Cl2CoN2O14S2
  40. Crystal structure of 2-(5-phenyl-1-(quinolin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenol, C24H19N3O
  41. Crystal structure of 2-((2-fluoro-4-(trifluoromethyl)phenyl)(hydroxy)methyl)-7-methoxy-3,4-dihydronaphthalen-1((2H))-one, C19H16F4O3
  42. Crystal structure of 2-amino-4-(2-fluoro-3-(trifluoromethyl)phenyl)-9-methoxy-1,4,5,6-tetrahydrobenzo[h]quinazolin-3-ium chloride, C20H18ClF4N3O
  43. Crystal structure of (2-phenylimino methylquinoline-κ 2 N,N′)-bis(1–phenylpyrazole-κ 2 C,N)-iridium(III) hexafluorophosphate, C34H26F6IrN6P
  44. Crystal structure of (3-hydroxy-4-methoxyphenyl)(pyrrolidin-1-yl)methanone, C12H15NO3
  45. The crystal structure of bis(trimethylsulfoxonium) catena-poly[µ2-hexabromido-indium(III)sodium(I)] C6H18O2S2NaInBr6
  46. Crystal structure of N-cyclopropyl-3-hydroxy-4-methoxybenzamide, C11H13NO3
  47. The crystal structure of (bis(benzimidazol-2-yl-methyl)amine-κ3N,N,N )-(dihydrogen L-malate-κ2O,O )copper(II) perchlorate dihydrate, CuC20H24ClN5O12
  48. Crystal structure of (1E,1′E)-4,4′-(9,9-diethyl-9H-fluorene-2,7-diyl)dibenzaldehyde dioxime, C31H28N2O2
  49. Crystal structure of diethyl 1,9-bis(4-fluorophenyl)-4,6-diphenylhexahydro-3H-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta [b]pyridine-3,7(2H)-dicarboxylate, C40H36F2N2O4
  50. Crystal structure of bis(benzene-1 carboxylato-O 3,5-carboxyl-κ1O)-[(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)nickel(II) ─ benzene-1,3,5-tricarboxylic acid ─ water (1/2/4), C52H66N4NiO28
  51. Crystal structure of 1,4-dibromo-2,5-bis(2-methoxyethoxy)benzene-1,4-diol, C12H16Br2O4
  52. Crystal structure of dicarbonyl[N,N′-(1,2-dimethyl-1,2-ethanediylidene)bis[2,6-bis(1-methylethyl)benzenamine]-N,N′]nickel(0), C30H40N2NiO2
  53. Crystal structure of 1,4-dibromo-2,5-bis(prop-2-yn-1-yloxy)benzene, C12H8Br2O2
  54. Crystal structure of O-(3-(benzo[d]thiazol-2-yl)naphthalen-2-yl) O-phenyl carbonothioate, C24H15NO2S2
  55. The crystal structure of (E)-4-fluoro-N′-(1-(4-hydroxyphenyl)propylidene)benzohydrazide, C16H15FN2O2
  56. Crystal structure of (E)-1-(benzo[d]thiazol-2-yl)-N-(4,5-dihydropyren-2-yl)methanimine, C24H16N2S
  57. Crystal structure of 3-((4-bromophenyl)thio)-1H-indole, C14H10BrNS
  58. Synthesis and crystal structure of 1-((7-hydroxy-3-(4-hydroxy-3-nitrophenyl)-4-oxo-4H-chromen-8-yl)methyl)piperidin-1-ium-4-carboxylate monohydrate, C22H22N2O9
  59. Synthesis and crystal structure of (3E,5S,10S,13S,14S,17Z)-17-ethylidene-10,13-dimethylhexadecahydro-3H-cyclopenta[α]phenanthren-3-one O-(methacryloyl) oxime, C50H74N2O4
  60. Crystal structure of the hydrogen storage active phase La12Mg46LiMn
  61. The crystal structure of the salt: 4-((1,3-dioxoisoindolin-2-yl)carbamoyl)pyridine-1-ium 2-carboxybenzoate, C14H10N3O3·C8H5O4
  62. Crystal structure of (2-(2-pyridine)-benzimidazole-κ2 N,N′)-bis(1-phenylpyrazole-κ2 C,N)iridium(III) hexafluorophosphate, C30H22F6IrN7P
  63. Crystal structure of dichlorido-bis[2-(2,4-difluorophenyl)pyridine-κ1N]platinum(II), C22H14Cl2F4N2Pt
  64. Crystal structure of (5R,8R,9R,10R,12R,13R,14R, 17S,17Z)-2-((3-fluoropyridin-4-yl)methylene)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)hexadecahydro-3H-cyclopenta[a]phenanthren-3-one, C36H52FNO3
Downloaded on 22.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2023-0417/html?lang=en
Scroll to top button